Abstract: The present invention relates to a method for assessing Atenolol with precision. A pharmaceutical composition comprising: a predefined amount of Atenolol or pharmaceutically acceptable salts thereof; and a combination of pharmaceutical excipients suitable for oral administration, wherein the method for tailoring the treatment of hypertension comprises of determining the levels of C-reactive protein, blood pressure, blood urea, and HbA1c in hypertensive patients; stratifying patients into distinct subgroups based on the identified biomarker levels; and customizing antihypertensive treatment plans for each subgroup, wherein treatment may include, but is not limited to, beta blockers such as Atenolol.

Abstract: A system for treating cancer and evaluating chemo-preventive potential of PHC and its prepared chitosan nanoparticles is described. The rats are divided into eight groups, from which group 1 is served as normal control, and group 2-8 are given single dose of DEN and repeated dose of CCl4, wherein freshly prepared solution of DEN in normal saline is used for the induction of HCC in rats by administering 200 mg/kg, i.p., PHC (2:1:1) in normal saline suspension to administer at doses of 900 mg/kg, wherein serum and tissue samples are collected after anesthetizing overnight fasted rats using intraperitoneal administration of thiopentone sodium at a dose of 40 mg/kg, wherein the collected serum and tissue samples is treated and thereby the chemo-preventive potential of PHC (2:1:1) and its prepared chitosan nanoparticles is evaluated upon determining liver markers, antioxidant parameters, total bilirubin, protein, lipid peroxidation, and liver cancer biomarkers.